Spectrum Pharmaceuticals Highlights Three Abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017

On June 2, 2017 Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, reported presentations of clinical data for FOLOTYN (pralatrexate injection) and MARQIBO (vinCRIStine sulfate LIPOSOME injection) to be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held in Chicago, Illinois, from June 2- 6, 2017 (Press release, Spectrum Pharmaceuticals, JUN 2, 2017, View Source [SID1234519351]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information about the ASCO (Free ASCO Whitepaper) Annual Meeting and for a complete list of abstracts, please refer to the conference website at View Source


FOLOTYN() (pralatrexate injection) related abstract:

Monday June 5, 2017, 8:00 AM-11:30 AM CDT

Abstract # Type Title First Author Location
7521
Poster Innovative approach to determine overall survival (OS) benefit for orphan diseases using case match control analyses (CMCA): The PROPEL experience of pralatrexate in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). O’Connor Hall A

MARQIBO (vinCRIStine sulfate LIPOSOME injection) related abstracts:

Saturday June 3, 2017, 3:00 PM-6:00 PM CDT

Abstract # Type Title First Author Location
7506 Oral Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL. Pfreundschuh S100bc

Monday June 5, 2017, 8:00 AM-11:30 AM CDT

Abstract # Type Title First Author Location
7539 Poster Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. Murawski Hall A